- Home
- HRZN vs SLN Comparison
HRZN vs SLN Comparison
Compare HRZN & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRZN
- SLN
- Stock Information
- Founded
- HRZN 2008
- SLN 1994
- Country
- HRZN United States
- SLN United Kingdom
- Employees
- HRZN N/A
- SLN N/A
- Industry
- HRZN Finance/Investors Services
- SLN Biotechnology: Pharmaceutical Preparations
- Sector
- HRZN Finance
- SLN Health Care
- Exchange
- HRZN Nasdaq
- SLN Nasdaq
- Market Cap
- HRZN 295.3M
- SLN 268.8M
- IPO Year
- HRZN 2010
- SLN N/A
- Fundamental
- Price
- HRZN $6.85
- SLN $4.60
- Analyst Decision
- HRZN Hold
- SLN Buy
- Analyst Count
- HRZN 4
- SLN 5
- Target Price
- HRZN $7.81
- SLN $32.60
- AVG Volume (30 Days)
- HRZN 624.6K
- SLN 53.7K
- Earning Date
- HRZN 10-28-2025
- SLN 11-13-2025
- Dividend Yield
- HRZN 19.27%
- SLN N/A
- EPS Growth
- HRZN N/A
- SLN N/A
- EPS
- HRZN N/A
- SLN N/A
- Revenue
- HRZN $97,144,000.00
- SLN $27,169,000.00
- Revenue This Year
- HRZN $0.51
- SLN N/A
- Revenue Next Year
- HRZN $9.90
- SLN N/A
- P/E Ratio
- HRZN N/A
- SLN N/A
- Revenue Growth
- HRZN N/A
- SLN 22.28
- 52 Week Low
- HRZN $6.77
- SLN $1.97
- 52 Week High
- HRZN $11.08
- SLN $20.48
- Technical
- Relative Strength Index (RSI)
- HRZN 36.75
- SLN 38.97
- Support Level
- HRZN $6.79
- SLN $4.77
- Resistance Level
- HRZN $6.97
- SLN $5.80
- Average True Range (ATR)
- HRZN 0.10
- SLN 0.36
- MACD
- HRZN 0.02
- SLN -0.04
- Stochastic Oscillator
- HRZN 19.46
- SLN 14.49
About HRZN Horizon Technology Finance Corporation
Horizon Technology Finance Corp is a specialty finance company. Its investment objective is to maximize its investment portfolio's total return by generating current income from the debt investments it makes and capital appreciation from the warrants it receives when making such debt investments. It lends to and invests in development-stage companies in the technology, life science, healthcare information and services, and sustainability industries.
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.